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Background: Pediculosis capitis is a worldwide health problem. One of the most important factor in effective head
lice eradication is to ensure that infestation is adequately recognized and treated. Our survey investigated the
knowledge and practice among primary care Italian pediatricians regarding to the prevention and treatment of
head lice.
Methods: The questionnaire was distributed to all the pediatricians registered at the Annual Congress of Practice in
Pediatrics held in Florence, Italy, November 11–12, 2011. It includes 10 questions in a multiple choice format, and
one answer for each question was provided. The questionnaire was conceived by pediatricians at the Infectious
Disease Unit of the Department of Science for the Health of Woman and Child, University of Florence. Questions
were designed according to the guidelines by the Italian Pediatric Society (SIP), and international guidelines, such
as the Centers for Disease Control and Prevention (CDC), and the American Academy of Pediatrics (AAP).
Results: Overall, 364/600 pediatricians (60.7% of physicians registered to the Congress) returned the questionnaire.
The majority of them (232/364; 63,7%) believe that parents consult their primary care pediatrician only after the
failure of other “remedies”. Mostly, they prescribe Malathion (116/364, 31,8%) as first line treatment. Two-hundred-
fourty-three (66.7%) of participants consider creams, foams and gels the most effective formulations. Two-hundred-
sixty-two of pediatricians interviewed (72.0%) suggest to repeat the treatment after one week, 37/364 (10.2%) after
two weeks. The majority of the pediatricians interviewed reported that recurrences occur in less than 30% of cases
(279/364; 76,6%). In their own opinion, most of recurrences are the consequence of a reinfestation in the
community (259/264; 77%). Three-hundred-thirty-four (91.7%) of them have never prescribed oral therapy for the
treatment of head lice. Finally, 289/364 (79.4%) pediatricians believe that no product is effective for prevention.
Conclusions: This is the first study that investigates the clinical practice of family pediatricians about the
management and treatment of head lice globally, the Italian pediatricians surveyed proved to be quite informed on
the head lice management. However, even in a country where pediatric assistance is free for everybody, a
considerable proportion of parents do not seek advice to their own family pediatrician. Therefore, educations of
parents, other than continuous updating of pediatricians, may contribute to a better management of head lice in
the community.
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Pediculosis capitis is a worldwide health problem. In high
resource countries, the overall prevalence of head lice
infestation is 1-3%, although there is a high variability
among countries. In Italy, a 2003 report exstimated an
incidence of 2-3% in general population [1], while in other
European countries prevalence ranges between 0.8 and
9.9% [2-7]. In the USA estimates range from 6 to 12
million cases of infestation per year [8]. Although the
infestation is characterized by a low morbidity, it may
cause a considerable social distress in term of discomfort
to the child, absences from school and expenses incurred
for treatment. Conventional topical pediculicides remain
the most commonly used form of treatment globally.
However, in the last 10 years, conventional therapy with
topical pediculicides is increasingly associated with treat-
ment failure and the emergence of resistance [9]. Many
factors are hypothesized to cause recidives: incorrect use
of pediculicides regarding to the dose and duration of the
treatment, type of formulation, residual pediculicide effect,
incorrect prophylaxis or intrinsic genetic resistance in lice
[10-13]. However, a considerable proportion of recidives
are a result of incorrect use of treatment rather than to in-
trinsic resistance in lice [14]. Therefore, the most important
factor in effective head lice eradication is to ensure that
infestation is adequately recognized and treated. Our
survey investigated the knowledge and practice among
primary care Italian pediatricians regarding to the preven-
tion and treatment of head lice.
Materials and methods
The questionnaire was distributed to all the pediatricians
registered at the Annual Congress of Practice in Pediatrics
held in Florence, Italy, November 11–12, 2011. This
meeting is one of the most important national meeting and
about 600 primary care pediatricians attend this meeting
every year from all over the country.
A self-administered, anonymous questionnaire was dis-
tributed to all the pediatricians at the Congress registration
desk. Overall, 600 questionnaires were distributed. The
survey was administered in Italian and translated into
English for publication. The English version of the ques-
tionnaire is enclosed in Additional file 1. It includes 10
questions in a multiple choice format. One answer for each
question was provided. The questionnaire was conceived
by pediatricians at the Infectious Disease Unit of the
Department of Science for the Health of Woman and Child,
University of Florence. Questions were designed according
to the guidelines by the Italian Pediatric Society (SIP) [15],
and international guidelines, such as the Centers for Dis-
ease Control and Prevention (CDC) [16], and the American
Academy of Pediatrics (AAP) [17]. Participants were asked
what kind of topical treatment they would first administer
in head lice and what kind of treatment they believe to bemore safe and effective in children <2 years. They were also
asked to specify whether and when pediculicides treatment
would be repeated, which formulation would be more
effective among shampoos, powders, creams, gels, foams
and sprays and the most effective attitude in preventing
transmission. Final questions explored the participants’
experience and opinion towards head lice recurrence and
their own attitude in case of reinfestation and infestation
recurrence, including administration of oral therapy.
Results
Overall, 364 pediatricians (60.7% of physicians registered
to the Congress) returned the questionnaire. The majority
of them ( 232/364; 63,7%) believe that parents ask to their
own friends, their relatives or the pharmacist or reading
news on Internet about the management of head lice,
rather then consulting their primary care pediatrician.
Moreover, we investigated the attitude towards the pre-
scription of pediculocides in all age groups and in children
younger than 2 years. Results are shown in Table 1.
Two-hundred-fourty-three (66.7%) of participants consider
creams, foams and gels the most effective formulations.
The remaining proportion of pediatricians believed that the
most effective formulations are shampoos (72/364; 19.7%)
or sprays (25/364; 6.8%) or powders (5/364; 1.4%). Two-
hundred-sixty-two of pediatricians interviewed (72.0%) sug-
gest to repeat the treatment after one week, 37/364 (10.2%)
after two weeks. A minority of them (58/364; 15.9%) does
not always repeat the treatment and a very low percentage
(4/364; 1.1%) repeat the treatment after 4 weeks.
Moreover, the majority of the pediatricians interviewed
reported that recurrences occur in less than 30% of cases
(279/364; 76,6%). In their own opinion, most of recurrences
are the consequence of a reinfestation in the community
(259/264; 77%), rather than lice intrinsic resistance to
pediculocides (22/364; 7%) or the incorrect use of these
products by parents (45/364; 14%). The pediatricians atti-
tude toward the repetition of a second full course of treat-
ment in case of recurrence/reinfestation is shown in Table 2.
Three-hundred-thirty-four (91.7%) of them have never pre-
scribed oral therapy for the treatment of head lice. Twenty-
four (6.5%) prescribed sulfamethoxazole-trimethoprim;
no-one has suggested treatment with oral ivermectine.
Finally, we investigated the attitude towards prevention
methods. Two-hundred-eighty-nine (79.4%) pediatricians
believe that no product is effective for prevention, while a
minority of them suggested preventive therapy with topical
pediculicides [19/364 (5.2%)], the disinfection of school
and home environments [40/364 (10.9%)], and only 6/364
(1.6%) the use of hats and headgear.
Discussion
This is the first study that investigates the clinical
practice of family pediatricians about the management
Table 1 Lice treatment in children < 2 years of age according to the first line treatment chosen
First line prescription treatment Treatment in children <2 years
Drugs N (%) Drugs N (%)
Permethrin 38/364 (10.4) Permethrin 13/38 (34.2 )
Other pirethroids and natural synergized pirethrins 3/38 (0.8)
Malathion 1/38 (0.3)
Natural oils 4/38 (10.5)
Dimeticone 11/38 (28.9)
Manual removal 4/38 (10.5)
I don’t know 2/38 (0.5)
Other pirethroids and natural synergized pirethrins 107/364 (29.4) Permethrin 3/107 (2.8)
Other pirethroids and natural synergized pirethrins 51/107 (47.7)
Malathion 0
Natural oils 6/107 (5.6)
Dimeticone 32/107 (29.9)
Manual removal 12/107 (11.2)
I don’t know 2/107 (1.9)
Malathion 116/364 (31.8) Permethrin 1/116 (0.9)
Other pirethroids and natural synergized pirethrins 12/116 (10.3)
Malathion 42/116 (36.2)
Natural oils 5/116 (4.3)
Dimeticone 31/116 (26.7)
Manual removal 15/116 (12.9)
I don’t know 10/116 (8.6)
Dimeticone 76/364 (20.9) Permethrin 0
Other pirethroids and natural synergized pirethrins 2/76 (2.6)
Malathion 1/76 (1.3)
Natural oils 3/76 (3.9)
Dimeticone 65/76 (85.5)
Manual removal 3/76 (3.9)
I don’t know 2/76 (2.6)
Natural oils 9/364 (2.5) Permethrin 0
Other pirethroids and natural synergized pirethrins 0
Malathion 0
Natural oils 7/9 (77.8)
Dimeticone 0
Manual removal 2/9 (22.2)
I don’t know 18/364 (4.9)
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focused on parental knowledges and attitudes [18-20]. Our
survey agrees with all these studies showing that parents
often seek advice firstly from the apothecary, or relatives, or
friends, and only after a failure from a physician.
Proper education of parents is an essential component
of the treatment of head lice, as well as clear treatment
plans. Three options are currently described for the
treatment of head lice: topical pediculocides, use of thecomb and oral therapy [15-17]. The preferred topical
pediculocides among these available in Italy are per-
methrin and other pyrethroyds, synergized pyrethrins,
and malathion. In our survey, we founded that only 10.4%
of the interviewed pediatricians choices permethrin as first
line treatment in head lice, while about one third of pedia-
tricians choices pirethroids and synergized pirethrins and
another third of them suggests 0.5% malathion. At the time
of our survey (2011), US and Italian guidelines suggested
Table 2 Percentage of recidives/reinfestations reported by pediatricians according to the first line prescription treatment
suggested, the second cicle of treatment proposed, and the time range recommended for the repetition of the treatment
Percentage of recidives/reinfestations
Rarely or less than 10% 30-50% I don’t know
n = 237 n = 118
N (%) N (%)
First line prescription treatment Permethrin (38/364) 22/38 (57.9) 14/38 (36.8) 2/38 (0.1)
Other pirethroids and natural pirethrins
synergized (107/364)
71/107 (66.3) 34/107 (31.8) 2/107 (0.0)
Malathion (116/364) 76/116 (65.5) 39/116 (33.6) 1/116 (0.0)
Natural oils (9/364) 9/9 (100) 0
Dimeticone (76/364) 49/76 (64.5) 24/76 (31.6) 3/76 (0.0)
I don’t know (5/364)
The second cicle of treatment suggested
in case of recidive/reinfestations
Repetition of a second complete cycle of treatment
of the same class as that used previously (220/364)
143/220 (71.5) 72/220 (32.7) 5/220 (0.0)
Repetition of a second complete cycle of treatment
of different class from that used previously (131/364)
85/131 (64.95) 44/131 (33.6) 2/131(0.0)
I don’t know (7/364)
Time range recommended for the
repetition of the treatment
No, not always. It depends on the product
used (58/364)
44/58 (75.8) 14/58 (24.1) 0
After 1 week (262/364) 164/262 (62.6) 93/262 (35.5) 5/262 (0.0)
After 2 weeks (37/364) 26/37 (70.3) 10/37 (27.0) 1/37 (0.0)
After 4 weeks (4/364) 2/4 (50.0) 0
I don’t know (2/364)
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head lice because of its efficacy and lack of toxicity [21].
However, resistance to 1% permethrin is increasingly been
reported [22-24]. Also other pirethroids (es. Phenotrin) and
pirethrins synergized, which are pyrethrins combined with
piperonyl butoxide, were considered as first choice by US
and Italian guidelines. As regards to malathion, both the
Italian and the US guidelines, published in 2010 and
therefore available at the moment of our survey, suggested
it as second choice, because of the odor, the flammability,
and the risk of respiratory depression if ingested [15-17].
Instead, the more recent 2012 UK guidelines [25] recom-
mend malathion as first line treatment. It’s of note that
there are some differences between the European and the
US formulation. First of all, the European formulation is in
an aqueous basis (even with a minimum alcohol content),
whereas the US formulation is more flammable, since it
contains 78% isopropyl alcohol. Moreover, malathion seems
to have less efficacy in Europe than in the US, probably be-
cause its continuous use in Europe during the past 30 years,
whereas in US it was withdrawed in 1990 and again in
1994 and definitively reintroduced in 1999. Moreover, the
formulation available only in the US (Ovide®), contains
isopropanol and terpenes, which seems to have its own
pediculocidal effects [26]. The results of our survey clearly
show the need of frequent updating and spreading at least
every 2 years national guidelines.A further finding of our survey is that nearly 50% of
pediatricians who prescribe a conventional topical pediculi-
cide as first line therapy, administrate the same treatment
in children under 24 months of age. As a matter of fact,
about 40% of pediatricians choice malathion as first line
treatment, and suggest this product also in children under
24 months. In general, conventional pediculicides are not
recommended in children younger than 2 years [27-29].
Furthermore, malathion is not recommended in children
younger than 6 years, because there are not enough studies
to support its safety, and it is moreover contraindicated in
children younger than 2 years [21].
It is also of note that about one fifth of pediatricians
prescribe dimethicone as first line treatment and only
40.1% prescribe it in children under 24 months. In fact,
in this age group, dimethicone could be an excellent
therapeutic tool, since it is odourless, non-toxic and
generally well tolerated by children from 6 months of age
[15-17]. It acts by coating the lice and causing suffocation
and has neither pediculocide nor ovocidal activity. A
study in the United Kingdom reported a cure rate of
nearly 70% [30], a study in Turkey reported cure rates
of 92% [31], and another large randomized trial conducted
in Brazil [32], in which a different formulation of
dimethicone was used (92% dimethicone), reported a 97%
cure rate. Maybe it is a new product, there are few studies
(all from the same authors), and Italian pediatricians
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if 2012 UK guidelines suggest di dimethicone as first line
treatment, we believe that more studies are needed to assest
efficacy and safety for young children.
Furthermore, only 11% of pediatricians suggest only
mechanical removal for children younger than 24 months.
Wet combing is the preferred treatment for children
younger than 2 years [27] and it also should be considered
if parents prefer not use a pediculocide on their child. Wet
combing is commonly suggested in association with topical
pediculocides, in order to improve their efficacy. However,
an observer-blinded study by Meinking TL, has investigated
the use of 1% permethrin creme with and without ad-
junctive combing and it has demonstrated the failure of
nit removal combing when made by non-professional
caregivers [33]. Maybe, when pediatricians suggest the
use of the comb, they should train parents to use the comb
as appropriate [25].
Finally, very few (3%) pediatricians suggest a treatment
with oils or other herbal products: their safety and efficacy
are currently unknown and they are not recommended [21].
Our survey also shows that oral pediculocides (Ivermectin
and Sulfamethoxazole-Trimethoprim) are, correctly,
very rarely prescribed. Recently (February 2012), topical
ivermectin lotion (Sklice®) was approved by the FDA. It
is indicated for the treatment of head lice in children
aged 6 months and older: it shows good therapeutic
perspectives [34,35].
Another result of our study is that the majority of
pediatrician interviewed (72%) recommend routine re-
treatment for all topical pediculocides, preferably on
day 7–9, as well as many experts suggest [21]. Improper
timing of second application of pediculicides should be
considered an important cause of treatment failure.
In literature there is a lack of data about the real inci-
dence of treatment failure in children. The majority of pe-
diatricians interviewed (65%) report a frequence of 10% or
less of short term recidives (<2 months from treatment),
while nearly one third reports a frequence rate between 30
and 50%. The majority of them believe that recidives are
attributable to a re-infestation in the childhood commu-
nity. More important, the ongoing presence of nits or itch
is not a sign of treatment failure, since nits could be not
alived. Only the finding of live lice, using a detection
comb, two or three days after completing a course
treatment (two applications of treatment 7 days apart)
should be considered a sign of treatment failure [25].
The persistence of living head lice after the use of
pediculocides may have several causes, such as: lack of
adherence of the patient to the treatment protocol; in-
adequate dosis or duration of treatment; re-infestation
(lice reacquired after treatment); and resistance of lice
to pediculocides. Several studies report an increasing rate
of lice resistance to topical pediculicides in the last years[13,36,37]. There are three main patterns of resistance:
genetic resistance (the presence of polymorphisms in
genes associated with resistance); clinical resistance
(persistence of live lice after a cycle of application);
parassitologic resistance (in vivo resistance of lice to
pediculocide compounds). As Durand R describes in a
recent review, permethrin-resistant phenotypes are mostly
associated with a recessive kdr trait, while no genetical
mechanism has been formally reported for malathion
[26]. Now, resistance rather than a lack of compliance
with treatment should be considered the main cause of
a treatment failure [38]. Currently, several strategies
have been proposed to overcome a possible treatment
failure. One of the strategies is the application of a product
for a full-course treatment and, in case of failure, the use
pediculocide with a different resistance profile [17,25]. Only
37% of pediatricians interviewed used this type of thera-
peutic approach. Probably, the restriction of pediculocides
availability only with medical prescription, the administra-
tion of these drugs at the right dose and with a correct tim-
ing may help in prevent treatment failure.
The main limit of our study is that over 40% of pedia-
tricians attending the conference did not respond to our
questionnaire and non-responders may be less updated
on national guidelines as compared to responder’s pedi-
atricians. Globally, the Italian pediatricians surveyed
proved to be quite informed on head lice management.
Moreover, pediatricians should advise parents that head
lice infestation should be diagnosed and treated under
the supervision of a physician. In fact, proper education of
parents, other than continuous updating of pediatricians,
may contribute to a better management of head lice in
the community.
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